Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis

NCT04081350 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT04081350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04081350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Lead sponsor
Nektar Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 4, 2019
Completion date
June 24, 2022
Enrollment
48 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic